Does the media refer more to EDIT or BEAM?

In the previous week, Beam Therapeutics had 4 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Beam Therapeutics and 1 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.50 beat Editas Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRSP or EDIT?

In the previous week, CRISPR Therapeutics had 14 more articles in the media than Editas Medicine. MarketBeat recorded 15 mentions for CRISPR Therapeutics and 1 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.72 beat Editas Medicine's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NTLA or EDIT?

In the previous week, Intellia Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 4 mentions for Intellia Therapeutics and 1 mentions for Editas Medicine. Intellia Therapeutics' average media sentiment score of 0.20 beat Editas Medicine's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, EDIT or XNCR?

Xencor has higher revenue and earnings than Editas Medicine. Xencor is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Editas Medicine $40.52M 10.23 -$160.06M -$0.75 N/A Xencor $125.58M 14.64 -$91.92M -$2.17 N/A

Is EDIT or XNCR more profitable?

Xencor has a net margin of -155.59% compared to Editas Medicine's net margin of -157.32%. Xencor's return on equity of -28.66% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Editas Medicine -157.32% -196.63% -38.17% Xencor -155.59% -28.66% -20.38%

Does the media favor EDIT or XNCR?

In the previous week, Editas Medicine and Editas Medicine both had 1 articles in the media. Xencor's average media sentiment score of 0.77 beat Editas Medicine's score of 0.00 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AGIO or EDIT?

In the previous week, Agios Pharmaceuticals had 10 more articles in the media than Editas Medicine. MarketBeat recorded 11 mentions for Agios Pharmaceuticals and 1 mentions for Editas Medicine. Agios Pharmaceuticals' average media sentiment score of 0.94 beat Editas Medicine's score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Editas Medicine (EDIT) Competitors

$2.70 -0.02 (-0.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.75 +0.05 (+1.85%)

As of 09/18/2026 07:50 PM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, XNCR, and AGIO

Should you buy Editas Medicine stock or one of its competitors? Editas Medicine's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Xencor (XNCR), and Agios Pharmaceuticals (AGIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Editas Medicine compare to Beam Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Editas Medicine has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Beam Therapeutics has a net margin of -54.75% compared to Editas Medicine's net margin of -157.32%. Beam Therapeutics' return on equity of -30.71% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Editas Medicine currently has a consensus target price of $6.00, suggesting a potential upside of 122.22%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 96.39%. Given Editas Medicine's higher probable upside, research analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Beam Therapeutics had 4 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Beam Therapeutics and 1 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.50 beat Editas Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A
Beam Therapeutics	$139.74M	18.44	-$79.99M	-$0.86	N/A

Summary

Beam Therapeutics beats Editas Medicine on 13 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Editas Medicine has a net margin of -157.32% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Editas Medicine	-157.32%	-196.63%	-38.17%

CRISPR Therapeutics presently has a consensus price target of $67.94, suggesting a potential upside of 20.12%. Editas Medicine has a consensus price target of $6.00, suggesting a potential upside of 122.22%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.59
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, CRISPR Therapeutics had 14 more articles in the media than Editas Medicine. MarketBeat recorded 15 mentions for CRISPR Therapeutics and 1 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.72 beat Editas Medicine's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,558.06	-$581.60M	-$4.76	N/A
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Intellia Therapeutics presently has a consensus price target of $20.98, suggesting a potential upside of 72.80%. Editas Medicine has a consensus price target of $6.00, suggesting a potential upside of 122.22%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Editas Medicine has a net margin of -157.32% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Editas Medicine	-157.32%	-196.63%	-38.17%

In the previous week, Intellia Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 4 mentions for Intellia Therapeutics and 1 mentions for Editas Medicine. Intellia Therapeutics' average media sentiment score of 0.20 beat Editas Medicine's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.14	-$412.69M	-$3.36	N/A
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A

Intellia Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Xencor?

Editas Medicine (NASDAQ:EDIT) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Editas Medicine has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Xencor has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Editas Medicine currently has a consensus target price of $6.00, suggesting a potential upside of 122.22%. Xencor has a consensus target price of $31.86, suggesting a potential upside of 28.87%. Given Editas Medicine's higher probable upside, research analysts plainly believe Editas Medicine is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Xencor has higher revenue and earnings than Editas Medicine. Xencor is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A
Xencor	$125.58M	14.64	-$91.92M	-$2.17	N/A

71.9% of Editas Medicine shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 5.1% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Editas Medicine and Editas Medicine both had 1 articles in the media. Xencor's average media sentiment score of 0.77 beat Editas Medicine's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a net margin of -155.59% compared to Editas Medicine's net margin of -157.32%. Xencor's return on equity of -28.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Xencor	-155.59%	-28.66%	-20.38%

Summary

Xencor beats Editas Medicine on 11 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

In the previous week, Agios Pharmaceuticals had 10 more articles in the media than Editas Medicine. MarketBeat recorded 11 mentions for Agios Pharmaceuticals and 1 mentions for Editas Medicine. Agios Pharmaceuticals' average media sentiment score of 0.94 beat Editas Medicine's score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has a net margin of -157.32% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Editas Medicine	-157.32%	-196.63%	-38.17%

Agios Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Agios Pharmaceuticals presently has a consensus target price of $41.25, suggesting a potential upside of 24.74%. Editas Medicine has a consensus target price of $6.00, suggesting a potential upside of 122.22%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

71.9% of Editas Medicine shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Editas Medicine has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	36.54	-$412.78M	-$7.01	N/A
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A

Summary

Agios Pharmaceuticals beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$414.67M	$3.89B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-3.60	14.23	275.49	25.40
Price / Sales	10.23	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	9.64	15.45	10.46	6.33
Net Income	-$160.06M	-$22.86M	$3.49B	$358.33M
7 Day Performance	N/A	-1.21%	0.59%	1.12%
1 Month Performance	-8.16%	-3.29%	-1.74%	-2.39%
1 Year Performance	-4.59%	37.74%	18.13%	5.35%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	1.6956 of 5 stars	$2.70 -0.7%	$6.00 +122.2%	-4.6%	$414.67M	$40.52M	N/A	87	High Trading Volume
BEAM Beam Therapeutics	2.0624 of 5 stars	$26.83 -9.5%	$49.00 +82.6%	+2.6%	$3.06B	$139.74M	N/A	510	High Trading Volume
CRSP CRISPR Therapeutics	2.4157 of 5 stars	$54.78 -1.8%	$68.06 +24.2%	-9.2%	$5.39B	$3.51M	N/A	460
NTLA Intellia Therapeutics	2.6685 of 5 stars	$12.74 flat	$21.15 +66.0%	-22.1%	$1.79B	$67.67M	N/A	600
XNCR Xencor	2.3427 of 5 stars	$25.33 -4.8%	$30.71 +21.3%	+140.2%	$1.98B	$125.58M	N/A	280

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, XNCR, and AGIO

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Xencor?

Summary

How does Editas Medicine compare to Agios Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, XNCR, and AGIO

How does Editas Medicine compare to Beam Therapeutics?

Which has more volatility and risk, EDIT or BEAM?

Do insiders and institutionals hold more shares of EDIT or BEAM?

Is EDIT or BEAM more profitable?

Do analysts rate EDIT or BEAM?

Does the media refer more to EDIT or BEAM?

Which has preferable earnings & valuation, EDIT or BEAM?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Which has more volatility and risk, CRSP or EDIT?

Do insiders and institutionals have more ownership in CRSP or EDIT?

Is CRSP or EDIT more profitable?

Do analysts rate CRSP or EDIT?

Does the media favor CRSP or EDIT?

Which has better valuation and earnings, CRSP or EDIT?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Do analysts recommend NTLA or EDIT?

Is NTLA or EDIT more profitable?

Does the media favor NTLA or EDIT?

Do institutionals and insiders have more ownership in NTLA or EDIT?

Which has stronger valuation & earnings, NTLA or EDIT?

Which has more risk and volatility, NTLA or EDIT?

Summary

How does Editas Medicine compare to Xencor?

Which has more volatility and risk, EDIT or XNCR?

Do analysts recommend EDIT or XNCR?

Which has better earnings and valuation, EDIT or XNCR?

Do institutionals & insiders have more ownership in EDIT or XNCR?

Does the media favor EDIT or XNCR?

Is EDIT or XNCR more profitable?

Summary

How does Editas Medicine compare to Agios Pharmaceuticals?

Does the media prefer AGIO or EDIT?

Is AGIO or EDIT more profitable?

Which has more volatility & risk, AGIO or EDIT?

Do analysts recommend AGIO or EDIT?

Do insiders and institutionals hold more shares of AGIO or EDIT?

Which has better valuation & earnings, AGIO or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools